301 related articles for article (PubMed ID: 18690826)
1. Design of self-immolative linkers for tumour-activated prodrug therapy.
Tranoy-Opalinski I; Fernandes A; Thomas M; Gesson JP; Papot S
Anticancer Agents Med Chem; 2008 Aug; 8(6):618-37. PubMed ID: 18690826
[TBL] [Abstract][Full Text] [Related]
2. Bioactivation of self-immolative dendritic prodrugs by catalytic antibody 38C2.
Shamis M; Lode HN; Shabat D
J Am Chem Soc; 2004 Feb; 126(6):1726-31. PubMed ID: 14871103
[TBL] [Abstract][Full Text] [Related]
3. Guided molecular missiles for tumor-targeting chemotherapy--case studies using the second-generation taxoids as warheads.
Ojima I
Acc Chem Res; 2008 Jan; 41(1):108-19. PubMed ID: 17663526
[TBL] [Abstract][Full Text] [Related]
4. Enzymatic activation of second-generation dendritic prodrugs: Conjugation of self-immolative dendrimers with poly(ethylene glycol) via click chemistry.
Gopin A; Ebner S; Attali B; Shabat D
Bioconjug Chem; 2006; 17(6):1432-40. PubMed ID: 17105221
[TBL] [Abstract][Full Text] [Related]
5. Remarkable drug-release enhancement with an elimination-based AB3 self-immolative dendritic amplifier.
Sagi A; Segal E; Satchi-Fainaro R; Shabat D
Bioorg Med Chem; 2007 Jun; 15(11):3720-7. PubMed ID: 17416532
[TBL] [Abstract][Full Text] [Related]
6. Modular theranostic prodrug based on a FRET-activated self-immolative linker.
Redy O; Shabat D
J Control Release; 2012 Dec; 164(3):276-82. PubMed ID: 22580227
[TBL] [Abstract][Full Text] [Related]
7. Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment.
Edupuganti VVSR; Tyndall JDATDA; Gamble AB
Recent Pat Anticancer Drug Discov; 2021; 16(4):479-497. PubMed ID: 33966624
[TBL] [Abstract][Full Text] [Related]
8. Modulating paclitaxel bioavailability for targeting prostate cancer.
Kumar SK; Williams SA; Isaacs JT; Denmeade SR; Khan SR
Bioorg Med Chem; 2007 Jul; 15(14):4973-84. PubMed ID: 17502149
[TBL] [Abstract][Full Text] [Related]
9. A chemical adaptor system designed to link a tumor-targeting device with a prodrug and an enzymatic trigger.
Gopin A; Pessah N; Shamis M; Rader C; Shabat D
Angew Chem Int Ed Engl; 2003 Jan; 42(3):327-32. PubMed ID: 12548691
[No Abstract] [Full Text] [Related]
10. Design of anticancer prodrugs for reductive activation.
Chen Y; Hu L
Med Res Rev; 2009 Jan; 29(1):29-64. PubMed ID: 18688784
[TBL] [Abstract][Full Text] [Related]
11. A self-immolative prodrug nanosystem capable of releasing a drug and a NIR reporter for in vivo imaging and therapy.
Wang Z; Wu H; Liu P; Zeng F; Wu S
Biomaterials; 2017 Sep; 139():139-150. PubMed ID: 28614754
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and pharmacological effects of a cyclization-activated steroid prodrug for colon targeting in inflammatory bowel disease.
Ruiz JF; Radics G; Windle H; Serra HO; Simplício AL; Kedziora K; Fallon PG; Kelleher DP; Gilmer JF
J Med Chem; 2009 May; 52(10):3205-11. PubMed ID: 19397323
[TBL] [Abstract][Full Text] [Related]
13. Prodrug strategies in anticancer chemotherapy.
Kratz F; Müller IA; Ryppa C; Warnecke A
ChemMedChem; 2008 Jan; 3(1):20-53. PubMed ID: 17963208
[TBL] [Abstract][Full Text] [Related]
14. In situ cross-linkable high molecular weight hyaluronan-bisphosphonate conjugate for localized delivery and cell-specific targeting: a hydrogel linked prodrug approach.
Varghese OP; Sun W; Hilborn J; Ossipov DA
J Am Chem Soc; 2009 Jul; 131(25):8781-3. PubMed ID: 19499915
[TBL] [Abstract][Full Text] [Related]
15. β-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: an update.
Tranoy-Opalinski I; Legigan T; Barat R; Clarhaut J; Thomas M; Renoux B; Papot S
Eur J Med Chem; 2014 Mar; 74():302-13. PubMed ID: 24480360
[TBL] [Abstract][Full Text] [Related]
16. New Taxol (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy.
Alaoui AE; Saha N; Schmidt F; Monneret C; Florent JC
Bioorg Med Chem; 2006 Jul; 14(14):5012-9. PubMed ID: 16554162
[TBL] [Abstract][Full Text] [Related]
17. Drug delivery by an enzyme-mediated cyclization of a lipid prodrug with unique bilayer-formation properties.
Linderoth L; Peters GH; Madsen R; Andresen TL
Angew Chem Int Ed Engl; 2009; 48(10):1823-6. PubMed ID: 19173369
[TBL] [Abstract][Full Text] [Related]
18. Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies.
Tietze LF; Krewer B
Chem Biol Drug Des; 2009 Sep; 74(3):205-11. PubMed ID: 19660031
[TBL] [Abstract][Full Text] [Related]
19. Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 (CPG2) showing large cytotoxicity differentials in GDEPT.
Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Lehouritis P; Marais R; Springer CJ
J Med Chem; 2003 Apr; 46(9):1690-705. PubMed ID: 12699387
[TBL] [Abstract][Full Text] [Related]
20. Lipid prodrug nanocarriers in cancer therapy.
Mura S; Bui DT; Couvreur P; Nicolas J
J Control Release; 2015 Jun; 208():25-41. PubMed ID: 25617724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
